Palmer D G, Barbezat G O, Gibbins B L, Grennan D M, Lum J, Myers D B, Wilson K
Curr Med Res Opin. 1981;7(6):359-69.
A single-blind crossover trial was carried out in 21 patients with active rheumatoid arthritis to assess the effectiveness and tolerance of sodium meclofenamate (300 mg per day) compared with placebo. After a 1-week washout period patients had two periods of active medication, each of 2 weeks, separated by 1 week on placebo. Morning stiffness, walking speed, pain score, patient impression of response, joint tenderness and power, work and maximum grip strength achieved by hand grip were all improved by sodium meclofenamate and an anti-inflammatory effect of the drug was demonstrated, with some reduction in the swelling of PIP joints. There was no advantage in assessing pain on full movement of the small joints of the hands in addition to direct tenderness. Power, work and rate of grip release achieved during hand grip provided more information about hand function than maximum grip strength alone. Lymphocyte transformation to non-specific mitogens was enhanced by the drug. Twelve patients had some form of gastro intestinal complaint during the study and it is suggested that diarrhoea is likely to prove to be the major limiting factor of acceptance by some patients.
对21例活动性类风湿性关节炎患者进行了一项单盲交叉试验，以评估甲氯芬那酸钠（每日300毫克）与安慰剂相比的有效性和耐受性。在1周的洗脱期后，患者接受两个为期2周的积极药物治疗阶段，中间间隔1周的安慰剂治疗。甲氯芬那酸钠可改善晨僵、步行速度、疼痛评分、患者对反应的印象、关节压痛和力量、手部握力测试所达到的工作能力和最大握力，证明了该药物的抗炎作用，近端指间关节肿胀也有所减轻。除了直接压痛外，评估手部小关节完全活动时的疼痛并无优势。手部握力测试期间的力量、工作能力和握力释放速率比单独的最大握力能提供更多关于手部功能的信息。该药物可增强淋巴细胞对非特异性有丝分裂原的转化。12名患者在研究期间出现了某种形式的胃肠道不适，提示腹泻可能是一些患者接受该药物的主要限制因素。
